BioPharm 生物制药

Pheromonicin Biotech, Ltd. | Protein Design Labs, Ltd.

PDL

Multi-peptides Selective Antibiotic Medicine

Artificial Multi-domain Protein Machine. Engineering multi-domain bactericidal peptide, a novel targeted antibiotic against antibiotic-resistant bacteria.

人造多结构域蛋白质分子机器。>针对多结构细菌基高分子多肽的生物工程方法，研制新型抗生药物 引领世界跨代生物制药科学趋向的创新发明。

With understanding about the plasticity and recombination of protein structures, a few multi-domain fusion proteins have been comprised with functional fragments of different proteins and artificial derivative peptides.

Protein Design Labs

Application: new organic bio-drug against bacteria, fungi, algae, cancer cells, etc.
Progress: toward 1st drug production approval mid-2011 (an animal mammal infection drug targeting the $10B world dairy industry market).

Inventor: Dr. Qiu Xiaoqing
Engineering: Li Rongqi
Academic Citations:

US Nature Biology 2003, 2007, 2010, UK Antimicrobial Agents and Chemotherapy 2005, China Frontier Sciences《前沿科技》2008, China NSF 2006-08, etc.

Innovative Biopharmaceutical Approach

  • Conventional biochemical means to:
    • Block build-up of cell membrane.
    • Sustain or disturb synthesis of proteins.
    • Sustain or disturb DNA synthesis and duplication.
  • PDL’s revolutionary approach combines:
    • Biophysical process to tunnel into cell membranes.
    • Bioengineering method to extract natural antibodies to emulating targeting processes.
  • Emulate and modify bacteria to create new drugs, the "tunneling" kill achieves "one molecule, one kill."
  • Tested independently in 9 labs in China and Europe:
    • 3-4 orders of magnitude stronger than regular penicillin, can be selective or wide-spectrum, triggers no antibiotic-adaptation, no allergic orside effects, and totally organic in production and use.
  • Patent licensing: Pheromonicin (BJ), Ltd. (a PDL JV) for animal health, PDL(Kunshan) for agriculture.
试验田：丘小庆, 李荣旗在四床雅安的第4年成功抗稻瘟病的实验田 治疗奶牛乳腺炎：丘小庆, 李荣旗在北京科润维德牛场的成功临床前实验 北京市科委生物医药发展中心－美国辉瑞公司Pfizer研发合作代表团：丘做介绍 稻页表面：丘小庆PMC-CA通过多肽农药聚集在真菌细胞表面，消灭稻瘟真菌 Test Drugs Qiu and Lee 靶向型多肽对耐药金葡菌株的杀菌活性超过苯唑西林数百倍，超过青霉素和先锋霉素近千倍，超过万古霉素数十倍

Technologies

  • In in vitro and in vivo experiments, fused proteins behaved demanding functions as we expected. They could be developed as a series of innovative antibiotic and anti-tumor drugs. By comparison with current drugs, they may have higher efficiency, better targeting ability and more safety as more ideal therapeutic agents.
  • Also Based upon these prototypes, it is available to construct molecular protein machine with more ideal functions.
  • Key words: linear structure, three-dimensional structure, domain parts, multi-domain protein machine.
  • Inventor: Dr. Qiu, Xiaoqing, Protein Designs (Beijing), Sichuan University of Medical Science.

Potential New Means to Fight

  • Virus
  • Bacteria
  • Fungi
  • Tumor

Academic Citations

US Nature Biolotechnology (2 published, 1 pending) ，China NSF (2006-08)，Frontier Sciences 前沿科技 (Q4, 2008).

FTC

Startup Business Development.

行业背景

自1944年青霉素抗投入使用以来，使细菌，尤其是威胁生命的致病菌，如金葡球菌、肺炎链球菌、绿脓杆菌、结核杆菌等已对其产生了广泛的耐药性。包括美国CDC历年发表的有关报告预测，化学药物的研发进入了艰难的时期，新的有效化学物质的合成和筛选日益困难。这些问题出现在人类，畜牧业和种植业。在农业领域过度使用抗生素和化学农药导致了农产品中的药物残留，直接影响到食品安全，威胁人类健康。

现有生物化学抗生素的抗性原理

  1. 阻止细胞壁的形成；
  2. 抑制或干扰蛋白质的合成；
  3. 抑制或干扰细菌DNA的合成与复制。

畿晋庆发明人的原理

同种细菌的不同家族之间为生存下去互相杀戮，分泌互相杀戮的抗菌物质，是生物物理过程，也是本发明的研究思路：借用同种细菌菌株之间互相抑制的杀菌方式—细菌素进行仿生改造，从而开发出完全创新的高效、无耐药或低耐药抗生素。 细菌素杀菌，甚至一个细菌素分子就有可能杀死一个细菌（One molecule, one kill）。
细菌素最有效的杀菌机制之一是通过在靶细菌膜上形成离子通道使细菌内含物泄漏、造成细胞的崩解而死亡。本发明利用的是从我们肠道中分离出的大肠杆菌毒素，在其羧基端联接上需要攻击的靶细菌的信息素，从而构成"生物导弹"。

杀伤效果（高效性）

本基因工程多肽对耐药金葡菌株的杀菌活性超过苯唑西林数百倍，超过青霉素和先锋霉素近千倍，超过万古霉素数十倍。其对鼠的致死剂量（LD50=250mg/L）是治疗剂量的200余倍。鼠急毒试验和生殖毒理试验证明对鼠无毒性。

发明人

丘小庆。工程应用: 李荣旗。畿晋庆三联生物技术 应用： 新型生态化生物制药，用于战胜。
  1. 人类和畜牧业病毒和病菌；
  2. 真菌和农业病虫害；
  3. 藻类；
  4. 肿瘤细胞；

学术认可

美国《自然.生物技术》(Nature Biotechnology)(三篇2004 ~ 2010), 中国自然科学基金 (2006-08), 中国科技部《前沿科技》(2009)。

容思睿智

创业商务开发。